Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

NCT00156286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Gleevec

Sponsor

University of Michigan Rogel Cancer Center